Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.

MLA

Elliot, Emilie R., et al. “Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.” Journal of Infectious Diseases, vol. 230, no. 1, July 2024, pp. e34–42. EBSCOhost, https://doi.org/10.1093/infdis/jiad580.

APA

Elliot, E. R., Polli, J. W., Patel, P., Garside, L., Grove, R., Barnett, V., Roberts, J., Byrapuneni, S., Crauwels, H., Ford, S. L., Solingen-Ristea, R. V., Birmingham, E., D’Amico, R., Baugh, B., & Wyk, J. van. (2024). Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials. Journal of Infectious Diseases, 230(1), e34–e42. https://doi.org/10.1093/infdis/jiad580

Chicago

Elliot, Emilie R, Joseph W Polli, Parul Patel, Louise Garside, Richard Grove, Vincent Barnett, Jeremy Roberts, et al. 2024. “Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.” Journal of Infectious Diseases 230 (1): e34–42. doi:10.1093/infdis/jiad580.